Bank of New York Mellon Corp Increases Position in Replimune Group, Inc. (NASDAQ:REPL)

Bank of New York Mellon Corp lifted its holdings in Replimune Group, Inc. (NASDAQ:REPL) by 7.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 174,518 shares of the company’s stock after purchasing an additional 11,893 shares during the period. Bank of New York Mellon Corp owned about 0.26% of Replimune Group worth $2,113,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of REPL. Braidwell LP increased its stake in Replimune Group by 203.0% during the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after buying an additional 2,057,460 shares in the last quarter. State Street Corp increased its stake in Replimune Group by 102.1% during the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after buying an additional 1,182,181 shares in the last quarter. Baker BROS. Advisors LP increased its stake in Replimune Group by 10.0% during the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock worth $121,057,000 after buying an additional 1,000,000 shares in the last quarter. Parkman Healthcare Partners LLC increased its stake in Replimune Group by 45.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company’s stock worth $8,371,000 after buying an additional 238,747 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Replimune Group by 17.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock worth $15,657,000 after buying an additional 217,308 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on REPL shares. BMO Capital Markets boosted their price objective on Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. HC Wainwright boosted their price objective on Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. boosted their price objective on Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Finally, Jefferies Financial Group upped their price target on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $19.43.

Replimune Group Trading Down 6.7 %

REPL opened at $10.82 on Friday. Replimune Group, Inc. has a one year low of $4.92 and a one year high of $17.00. The stock has a market capitalization of $833.30 million, a PE ratio of -3.52 and a beta of 1.30. The business’s 50 day moving average price is $12.66 and its 200 day moving average price is $12.14. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). As a group, equities research analysts expect that Replimune Group, Inc. will post -2.97 EPS for the current year.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.